47P Prevalence of mutations in common tumour types in Northern England and utility of Experimental Cancer Medicine Centre (ECMC) CRUK Trial Finder

Genomic profiling of tumours has expanded rapidly, and is of increasing importance in early phase trial units in matching patients to targeted clinical trials. It is recognised that mutational signatures vary by demographic group, however, regional differences are not yet characterised. This was investigated by comparing relative prevalence of mutations for common cancers presenting to Newcastle ECMC to The Cancer Genome Atlas (TCGA) and comparative utility of trial matching modalities within and outside the UK.